Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Equitable Holdings Inc. Common Stock (EQH) vs Philip Morris International Inc. (PM) Price & Performance

Equitable Holdings Inc. Common StockTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

Equitable Holdings Inc. Common Stock vs Philip Morris International Inc. — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B), while Philip Morris International Inc. trades at $209 (market cap $310.62B). The key difference: Philip Morris International Inc. is far larger — about 21.4× Equitable Holdings Inc. Common Stock's market cap, and Philip Morris International Inc. pays the higher dividend (3.21%). Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Philip Morris International Inc. for 85 Days on average.

EQHPM
Market Cap
$14.49B$310.62B
Volume
2,405,4014,145,126
Sector
FinancialsConsumer Staples
52-Week High
$54.50$205.58
52-Week Low
$35.34$144.33
Typical Hold Time
0 Days85 Days
Enterprise Value
$5.54B$353.73B
Dividend Yield
2.15%3.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Equitable Holdings Inc. Common Stock

Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.

EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.

Philip Morris International Inc.

Philip Morris International (PM) trades at $199.29, down 1.34% on the day, with strong earnings momentum after beating Q1 and Q2 2026 EPS estimates. The company shows robust fundamentals with 2025 revenue of $40.65B and net income margin of 25.56%, though valuation ratios appear elevated. Technical indicators show a bullish moving average trend but overbought RSI signals, with key support at $199. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now representing over 40% of revenue.

PM's outlook remains positive with analyst consensus price target of $212.17 (6.5% upside) and 68% buy ratings. Growth is driven by smoke-free product adoption and international expansion, but risks include regulatory pressures, high debt levels, and premium valuation. The stock offers dividend income with recent $1.60 payout, supporting total return potential for investors comfortable with tobacco sector exposure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EQH
100% Buy0% Sell
Avg holding period · 0 Days
PM
32% Buy68% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About Equitable Holdings Inc. Common Stock

Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.

Read more on EQH →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →